Dear Oncology Professional:
The oncology landscape is accelerating quickly. New agents, combination therapies, new technologies and targeted therapies are resulting in improved treatment and maintenance options for our patients. Our overall approach to medicine is rapidly evolving and oncology is leading the way in the reality of personalized medicine.
I’d like to personally invite you to New Frontiers in the Management of Solid and Liquid Tumors
. My colleague, leukemia chief Stuart Goldberg, MD, and I are the Program Chairs and can promise you this will be an exciting professional education opportunity that will provide relevant, important new information, stimulating discussions, and an opportunity to personally meet your colleagues from across the globe.
The complimentary CME program will be hosted November 3-4 at the John Theurer Cancer Center and feature world-class physicians who are leading cutting-edge research into the state-of the-art treatment modalities for hematological and solid tumors. We’ll be addressing the following important topics:
Emerging best practices and studies in hematological malignancies and solid tumors
Impact of novel therapies in the care of hematology-oncology and solid tumor patients
New modalities in imaging and its best use in cancer patients
Biomarkers and new prognostic markers in lymphomas and leukemias
Impact of emerging molecular markers in solid tumors
Shifting paradigms in the treatment of multiple myeloma
To view the complete agenda and register online, visit www.jtcancercenter.org/CME
. I hope you can join us for this important event and I look forward to seeing you there.
Andre Goy, MD, MS
Editor-in-Chief, Contemporary Oncology
Chairman, Director and Chief, Division of Lymphoma
John Theurer Cancer Center at Hackensack University Medical Center